Skip to content
RNAWiki

Arformoterol

  • Prescription medicine
  • Prescription only
  • Identity checked
  • Sources last checked 2026-09-04

This page shows what was measured, who it was measured in, and what that does not settle.

What Arformoterol does in the body

Arformoterol tartrate inhalation solution is a long-acting beta 2 -adrenergic agonist (beta 2 -agonist) indicated for: Long-term, twice daily (morning and evening) administration in the maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.

From the FDA-approved label: Arformoterol, the (R,R)-enantiomer of formoterol, is a selective long-acting beta 2 -adrenergic receptor agonist (beta 2 -agonist) that has two-fold greater potency than racemic formoterol (which contains both the (S,S) and (R,R)-enantiomers). The (S,S)-enantiomer is about 1,000-fold less potent as a beta 2 -agonist than the (R,R)-enantiomer. While it is recognized that beta 2 -receptors are the predominant adrenergic receptors in bronchial smooth muscle and beta 1 -receptors are the predominant receptors in the heart, data indicate that there are also beta 2 -receptors in the human heart comprising 10% to 50% of the total beta-adrenergic receptors.

Why people take it. Arformoterol tartrate inhalation solution is a long-acting beta 2 -adrenergic agonist (beta 2 -agonist) indicated for: Long-term, twice daily (morning and evening) administration in the maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.

What happened in people

RNAWiki has not yet published a reviewed conclusion for this use.

A fixed RNAWiki sentence

Where this came from

Wording RNAWiki always uses, not a finding about this substance.

No reviewed claim names a result for any goal on this record.

No source is stored against this line.

The limit that matters most

Not recorded.

Where it acts
Not recorded.
Kind of result
No result is published, so no kind of result applies yet
Supervision
RNAWiki has not recorded a supervision or regulatory status for this substance.

What the registries record it as

  • The substance registry classes this as chemical.

    FDA substance registry · F91H02EBWT · read 2026-08-29

  • Its recorded molecular formula is C19H24N2O4•C4H6O6, weighing 494.5 g/mol.

    US prescribing information · 6838a595-19cc-454a-96b9-ff83b93881ae · read 2026-08-30

Where each sentence above came from

The use the label states, quoted from it. No plain-language version of this sentence has been written.

The use the label states, quoted from it. It is written for a clinician, not for a reader without medical training.

No statement of the main limit is recorded.

The four opening statements run to 206 words.

Words this page uses

Four words worth knowing first

Chosen from what this page shows, with each one explained before the word it depends on.

Biomarker

A biomarker is a number from a test that stands in for something about health.

A picture of it, and where the picture fails

A biomarker is like a fuel gauge.

Where that stops being true. A gauge is wired to the tank. Many biomarkers are only loosely tied to health.

What people get wrong. A better number is read as a better life. Several medicines improved a number and helped nobody.

A measurable indicator used as a substitute for a clinical outcome of interest.

Placebo

A placebo is a dummy treatment given so the real one can be compared with it.

A picture of it, and where the picture fails

A placebo is like a blank control in an experiment.

Where that stops being true. A blank does nothing. People given a placebo often do get better.

What people get wrong. A placebo effect is read as imaginary. The improvement is measured and real.

An inactive intervention matched in appearance to the test intervention, used to control for non-specific effects.

Comparator

A comparator is whatever the treatment was measured against.

A picture of it, and where the picture fails

It is like the other runner in a race.

Where that stops being true. A race has one winner. A study can show both arms improved.

What people get wrong. Results are read without asking what the other group got. Beating nothing is not beating a treatment.

The control condition against which the experimental intervention is assessed.

What happened in peopleRead from sources, not yet reviewed

What happened in people

Each card is one study: the exact question it asked, who was in it, and whether it showed what it set out to show.

Number of Participants Experiencing an Event in the Composite Endpoint (Asthma-related Death, Asthma-related Intubation or Asthma-related Hospitalization)

The study did not show it

Who was studied
NCT01444430
How many people
12460
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
Living longer, or avoiding a major event
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated

What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.

The limits of this study, and where it came from

Main limit. No limitation is recorded for this study.

How far it carries. This study is recorded from the curated record, not from the registry match.

Form and route. Inhalation

Interval reported. Not recorded in this summary

Written into the record, not signed off as a reviewed claim.

  • openFDA Drugs@FDA · a recorded source, not a stored snapshot
  • openFDA NDC Directory · a recorded source, not a stored snapshot
  • openFDA SPL label · a recorded source, not a stored snapshot
  • PubChem PUG-REST · a recorded source, not a stored snapshot

Time-to-First Serious Asthma Outcomes (SAO): Number of First SAO in the MF/F vs MF Arms

The study did not show it

Who was studied
NCT01471340
How many people
11744
Study design
Phase 4
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated

What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.

The limits of this study, and where it came from

Main limit. No limitation is recorded for this study.

How far it carries. This study is recorded from the curated record, not from the registry match.

Form and route. Inhalation

Interval reported. Not recorded in this summary

Written into the record, not signed off as a reviewed claim.

  • openFDA Drugs@FDA · a recorded source, not a stored snapshot
  • openFDA NDC Directory · a recorded source, not a stored snapshot
  • openFDA SPL label · a recorded source, not a stored snapshot
  • PubChem PUG-REST · a recorded source, not a stored snapshot

Adjusted Rate of Moderate or Severe Exacerbations

The study did not show it

Who was studied
NCT02465567
How many people
8588
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated

What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.

The limits of this study, and where it came from

Main limit. No limitation is recorded for this study.

How far it carries. This study is recorded from the curated record, not from the registry match.

Form and route. Inhalation

Interval reported. Not recorded in this summary

Written into the record, not signed off as a reviewed claim.

  • openFDA Drugs@FDA · a recorded source, not a stored snapshot
  • openFDA NDC Directory · a recorded source, not a stored snapshot
  • openFDA SPL label · a recorded source, not a stored snapshot
  • PubChem PUG-REST · a recorded source, not a stored snapshot

Number of Severe Asthma Exacerbations Per Participant.

The study did not show it

Who was studied
NCT00463866
How many people
8424
Study design
Phase 4
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated

What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.

The limits of this study, and where it came from

Main limit. No limitation is recorded for this study.

How far it carries. This study is recorded from the curated record, not from the registry match.

Form and route. Inhalation

Interval reported. Not recorded in this summary

Written into the record, not signed off as a reviewed claim.

  • openFDA Drugs@FDA · a recorded source, not a stored snapshot
  • openFDA NDC Directory · a recorded source, not a stored snapshot
  • openFDA SPL label · a recorded source, not a stored snapshot
  • PubChem PUG-REST · a recorded source, not a stored snapshot

Time to first severe cardiac or COPD event

The study did not show it

Who was studied
NCT06283966
How many people
5250
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated

What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.

The limits of this study, and where it came from

Main limit. No limitation is recorded for this study.

How far it carries. This study is recorded from the curated record, not from the registry match.

Form and route. Inhalation

Interval reported. Not recorded in this summary

Written into the record, not signed off as a reviewed claim.

  • openFDA Drugs@FDA · a recorded source, not a stored snapshot
  • openFDA NDC Directory · a recorded source, not a stored snapshot
  • openFDA SPL label · a recorded source, not a stored snapshot
  • PubChem PUG-REST · a recorded source, not a stored snapshot

Annual Severe Asthma Exacerbation Rate - Non-inferiority Analysis

The study did not show it

Who was studied
NCT02224157
How many people
4215
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated

What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.

The limits of this study, and where it came from

Main limit. No limitation is recorded for this study.

How far it carries. This study is recorded from the curated record, not from the registry match.

Form and route. Inhalation

Interval reported. Not recorded in this summary

Written into the record, not signed off as a reviewed claim.

  • openFDA Drugs@FDA · a recorded source, not a stored snapshot
  • openFDA NDC Directory · a recorded source, not a stored snapshot
  • openFDA SPL label · a recorded source, not a stored snapshot
  • PubChem PUG-REST · a recorded source, not a stored snapshot
What we know
RNAWiki holds 6 written-up human studies for this substance, each with the question it asked.
How we know it
Each card names the study, the number of people and what the study set out to measure.
What this does not prove
These summaries were written by a person and have not been signed off as reviewed claims.
Why it matters
A study that failed is as informative as one that worked, and both are here.
What we still do not know
No reviewed claim exists, so no exact population, effect size or interval is published yet.

What is missing or unclearRead from sources, not yet reviewed

Were people like you studied?

RNAWiki cannot tell whether a study fits you. It can show who was in it, and where the result stops carrying.

Who was studied

People similar to this profile were included.

  • Arformoterol tartrate inhalation solution is a long-acting beta 2 -adrenergic agonist (beta 2 -agonist) indicated for: • Long-term, twice daily (morning and evening) administration in the maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.

Who is missing from the studies

  • Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.

What the label states about particular groups

  • On pediatric, the label states: “The safety and efficacy of arformoterol tartrate inhalation solution in pediatric patients have not been established.”

    US prescribing information · 6838a595-19cc-454a-96b9-ff83b93881ae · read 2026-08-30

  • On older people, the label states: “Of the 873 patients who received arformoterol tartrate inhalation solution in two placebo-controlled clinical studies in adults with COPD, 391 (45%) were 65 years of age or older while 96 (11%) were 75 years of age or older.”

    US prescribing information · 6838a595-19cc-454a-96b9-ff83b93881ae · read 2026-08-30

  • On people who are pregnant, the label states: “Risk Summary There are no adequate and well-controlled studies in pregnant women.”

    US prescribing information · 6838a595-19cc-454a-96b9-ff83b93881ae · read 2026-08-30

  • On people who are breastfeeding, the label states: “Risk Summary There are no data on the presence of arformoterol or its metabolites in human milk, the effects on the breastfed infant, or the effects on milk production.”

    US prescribing information · 6838a595-19cc-454a-96b9-ff83b93881ae · read 2026-08-30

  • On people with reduced liver function, the label states: “Arformoterol tartrate inhalation solution should be used cautiously in patients with hepatic impairment due to increased systemic exposure in these patients [ see Clinical Pharmacology ( 12.3 ) ].”

    US prescribing information · 6838a595-19cc-454a-96b9-ff83b93881ae · read 2026-08-30

  • On people with reduced kidney function, the label states: “The systemic exposure to arformoterol was similar to renally impaired patients compared with demographically matched healthy control subjects [ see Clinical Pharmacology ( 12.3 ) ].”

    US prescribing information · 6838a595-19cc-454a-96b9-ff83b93881ae · read 2026-08-30

Where the result stopped carrying

  • This is a scope explorer, not a diagnosis engine.
  • It shows who was studied so you can see whether people similar to you were included.

RNAWiki cannot tell whether a study fits you. It can show who was in it.

What it would be like to takeRead from sources, not yet reviewed

Why it might seem to do nothing

A real effect and a noticed effect are different things. These are the recorded reasons the two come apart.

It was studied in different people

The people in the studies were not much like the reader.

On this record: Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.

The evidence may simply be wrong

Small early studies often do not hold up.

On this record: RNAWiki has not yet published a reviewed conclusion for this use.

Other reasons RNAWiki checked and found nothing for (11)
It was studied for a different goal
The studies measured something else entirely. Nothing in this record points to this reason.
A different form was studied
The studied form is not the form on the shelf. Nothing in this record points to this reason.
There was nothing to correct
Where a level is already normal, topping it up may change nothing. Nothing in this record points to this reason.
Something else had to happen too
In the studies it was paired with training, a diet or another treatment. Nothing in this record points to this reason.
The change is too small to feel
A real change can still sit below what a person notices. Nothing in this record points to this reason.
Day-to-day swing hides it
Sleep, food, stress and time of day move most numbers more than this would. Nothing in this record points to this reason.
Not enough time yet
The studies ran longer than the person has waited. Nothing in this record points to this reason.
It was not taken as studied
Missed days change the result, and studies count them. Nothing in this record points to this reason.
Something else changed at the same time
Two changes at once cannot be told apart afterwards. Nothing in this record points to this reason.
The product may not be what it says
Contents of a sold product are not always what the label states. Nothing in this record points to this reason.
No recorded reason
RNAWiki has nothing stored that would explain it. Nothing in this record points to this reason.

None of these is a reason to take more. Taking more is not a step this page ever suggests.

What it would be like to takeRead from sources, not yet reviewed

What taking it involves

The recorded facts about getting hold of it and using it. Nothing here is a suggestion about what you should do.

How it is supplied

Prescription only

Quoted from a source

Where this came from

Copied from a source RNAWiki stored, with the source named.

Read from the recorded approval status.

No source is stored against this line.

Form and route

Inhalation

Source-linked record

Where this came from

A person wrote this into the record with the study named beside it. No reviewer has signed it off.

The form and route recorded on this substance.

No source is stored against this line.

Who oversees it

RNAWiki has not recorded a supervision or regulatory status for this substance.

Quoted from a source

Where this came from

Copied from a source RNAWiki stored, with the source named.

No register row and no identity class settled the question.

No source is stored against this line.

What is in the pack

Sold as solution, given by the inhalation, respiratory (inhalation) route.

Source-linked record

Where this came from

A person wrote this into the record with the study named beside it. No reviewer has signed it off.

Recorded notes on how this is sold and what that means for what is in the pack.

No source is stored against this line.

Where it is registered

Regulatory records are listed in the technical disclosure at the foot of this page.

Counted from records

Where this came from

A count of rows RNAWiki holds. It describes our records, not your body.

Register entries are stored per jurisdiction and shown with their dates.

No source is stored against this line.

Why people stop

Not recorded.

Nothing recorded

Where this came from

RNAWiki holds nothing here and says so rather than guessing.

No record of why people stopped taking it is stored for this substance.

No source is stored against this line.

What it would be like to takeNothing found in the sources checked

What can go wrong

Sorted by where each line came from. A regulator's label and a report somebody sent in are not the same kind of fact.

Nothing found in the sources checked

No harm is recorded against this substance in the sources RNAWiki checked. Finding nothing is not the same as showing there is nothing.

The sources listed were searched and held nothing. That is not the same as nothing existing.

Over a long time. No completed tested study window is recorded, so long-term effects are not established by the registry record.

Groups the studies covered thinly. Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.

What is missing or unclearRead from sources, not yet reviewed

Does the exact form matter?

Evidence belongs to the exact thing that was tested. A different salt, a different mixture or a different preparation is a different question.

The form that was studied

Inhalation

Source-linked record

Where this came from

A person wrote this into the record with the study named beside it. No reviewer has signed it off.

The form used in the studies cited on this page.

No source is stored against this line.

What is sold

Not recorded.

Nothing recorded

Where this came from

RNAWiki holds nothing here and says so rather than guessing.

Nothing further is recorded about which forms are sold.

No source is stored against this line.

What is recorded as being sold

  • 20 products list this as an active ingredient in the United States drug directory. 20 of them contain it and nothing else.

    FDA National Drug Code directory · 72266-259 · read 2026-08-29

  • They are sold as powder and solution, taken respiratory (inhalation).

    FDA National Drug Code directory · 72266-259 · read 2026-08-29

  • The regulator's established pharmacologic class for it is adrenergic beta2-agonists [moa] and beta2-adrenergic agonist [epc].

    FDA National Drug Code directory · 72266-259 · read 2026-08-29

  • 15 published labels name it as an active ingredient. 15 of them describe this substance alone, which is where its own label text on this page comes from.

    US prescribing information · 6838a595-19cc-454a-96b9-ff83b93881ae · read 2026-08-29

  • Those labels are classed as human prescription drug.

    US prescribing information · 6838a595-19cc-454a-96b9-ff83b93881ae · read 2026-08-29

  • Arformoterol Tartrate is respiratory (inhalation) at 3 DOSAGE FORMS AND STRENGTHS Arformoterol tartrate inhalation solution is supplied as a sterile solution for nebulization in low-density polyethylene unit-dose vials., recorded as fda label in effect 2025-04-18 in the United States.

    US prescribing information · 6838a595-19cc-454a-96b9-ff83b93881ae · read 2026-08-30

  • Recorded price in US: 0.6145–0.64287 USD per one millilitre, across 27 priced products whose strengths and pack forms differ, as of 2026-08-26, paid by retail pharmacies buying the product, as surveyed by the Centers for Medicare & Medicaid Services. It is not a list price, an insurance price, or what anyone pays at a counter..

    Recorded source · 2026-08-26 · read 2026-08-28

Evidence carries across two names for one substance. It does not carry across a salt, a mirror form or a mixture.

What it would be like to takeRead from sources, not yet reviewed

What you could measure

This one is decided with a clinician, so this section holds questions to ask rather than a plan to run.

RNAWiki could not confidently classify this substance, so no self-experiment plan is offered.

Questions worth asking

  • Which of the trials of Arformoterol studied people like me?
  • What was measured, and for how long?
  • Was the result a laboratory value or a health outcome?
  • What would we watch for, and when would we stop?

Tracking can show whether something changed for you. It cannot show what caused it.

RNAWiki records evidence. It does not say whether this substance is right for you.

What is missing or unclearRead from sources, not yet reviewed

What nobody knows yet

Open questions, each with why it is open and what would close it.

Missing populations

Which groups were under-represented in the studies has not been recorded.

Why it matters. Recorded by the evidence model as a gap on this record.

What would answer it

A study that measures it, and a reviewer to sign it off.

Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.

Missing long-term data

No completed tested study window is recorded.

Why it matters. Recorded by the evidence model as a gap on this record.

What would answer it

A study that measures it, and a reviewer to sign it off.

Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.

No reviewed conclusion

RNAWiki has not yet published a reviewed conclusion for this use.

Why it matters. Recorded by the evidence model as a gap on this record.

What would answer it

A study that measures it, and a reviewer to sign it off.

Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.

Missing interaction studies

No interaction was found in the registers checked. Not finding one is not the same as showing there is none.

Why it matters. Recorded by the evidence model as a gap on this record.

What would answer it

A study that measures it, and a reviewer to sign it off.

Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.

Formulation uncertainty

Several salts, forms or products of Arformoterol are recorded. Results from one form may not transfer to another.

Why it matters. Recorded by the evidence model as a gap on this record.

What would answer it

A study that measures it, and a reviewer to sign it off.

Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.

Mechanism not reviewed

No reviewed mechanism story exists for this substance.

Why it matters. Recorded by the evidence model as a gap on this record.

What would answer it

A study that measures it, and a reviewer to sign it off.

Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.

What happened in peopleRead from sources, not yet reviewed

Check any of this yourself

Every line above traced back to the study it came from. This is the technical layer, and the vocabulary changes here.

How many documents were read

  • 12 documents were read for this substance.

    RNAWiki source record

  • 12 of them state the same halfLife, and they agree.

    RNAWiki source record

Where else this substance is registered

FDA substance identifier (UNII)
F91H02EBWT
CAS registry number
67346-49-0
PubChem compound
3083544
ChEMBL
CHEMBL1363
ChEBI
408174
WHO international nonproprietary name list entry
8398
RxNorm concept
304962
EMA substance identifier
100000128220
DrugBank
DB01274

Checks this page had to pass

  • Passed

    Identity resolved

    no open identity hold

  • Passed

    No unresolved merge across substance families

    no quarantine open

  • Passed

    Every public sentence names a source

    The opening statement carries the origin: Quoted from a stored source.

  • Not passed

    Trial roles classified for highlighted evidence

    No registered study is classified as testing this substance.

  • Passed

    No internal keys in reader text

    enforced by the copy-contract test over the rendered page

  • Not passed

    Safety mode resolved

    No register row and no identity class settled the question.

  • Passed

    Canonical metadata present

    slug and display name present

What is missing or unclearRead from sources, not yet reviewed

How this medicine reached us

Kept near the foot of the page. A historical event moves up only when it changes something about this substance today.

What the approval register records

  • 18 approved applications cover products containing this substance. The earliest was NDA021912, approved 20061006 to LUPIN.

    Drugs@FDA application register · NDA021912 · read 2026-08-29

  • Marketing status on the register: discontinued and prescription.

    Drugs@FDA application register · NDA021912 · read 2026-08-29

  • The earliest marketing start date recorded for a listed product is 20061006.

    FDA National Drug Code directory · 72266-259 · read 2026-08-29

What is missing or unclearRead from sources, not yet reviewed

What to learn next

Ordered by what would most change how you read this page, starting with what is easiest to misunderstand.

This order is fixed in code and does not count clicks or time on the page.

What is not here

9 questions this page could not answer

These sections were prepared and left out because there was nothing to put in them. They are listed rather than hidden, so the gaps in this record are visible.

  • What was measured, goal by goal — found nothing in the sources checked.
  • How close this is to real life — found nothing in the sources checked.
  • The path through the body — found nothing in the sources checked.
  • Felt, measured, or meaningful — found nothing in the sources checked.
  • How long anything takes — found nothing in the sources checked.
  • What it may clash with — found nothing in the sources checked.
  • Other ways to the same goal — found nothing in the sources checked.
  • Claims that go past the evidence — found nothing in the sources checked.
  • What changed on this page — found nothing in the sources checked.

The record as stored

The full record, for auditing

Everything above is built from what is below. This layer keeps the technical vocabulary, record identifiers and every stored row, so a reader who wants to check the page can.

Recorded evidence blocks (10)

On the Arformoterol label: indicated for what?

"Arformoterol tartrate inhalation solution is a long-acting beta 2 -adrenergic agonist (beta 2 -agonist) indicated for: Long-term, twice daily (morning and evening) administration in the maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic…": indications and usage on Arformoterol's label. DailyMed label · bb1a6643-f280-4f02-a824-0428a2b82d3c · 2026-08-20

151 registered trials of Arformoterol — at which phases?

Registered studies posting no result
92 of 151

151 registered studies of Arformoterol: 48 phase3, 41 phase2, 35 phase4, 13 na, 9 na or unstated, 8 phase1. CLINICALTRIALS_SNAPSHOT · 2026-09-01

14 with a PubMed record

Show the evidence
  • phase3
    48
  • phase2
    41
  • phase4
    35
  • na
    13
  • na or unstated
    9
  • phase1
    8
7 more recorded rows
  • completed
    115
  • unknown
    12
  • terminated
    10
  • recruiting
    6
  • withdrawn
    6
  • active not recruiting
    1
  • not yet recruiting
    1

recorded 2026-09-01 · last checked 2026-09-04

15 of Arformoterol's trials stopped: accrual/recruitment, funding/business, other?

accrual/recruitment (5), funding/business (4) and other (6): Arformoterol's stop wording, clustered. CLINICALTRIALS_SNAPSHOT · 2026-09-01

"Sponsor withdrew funding prior to study initiation"; 15 of 151 registered studies

Show the evidence

Trial

  • NCT00633776
    withdrawn; "Sponsor withdrew funding prior to study initiation"
  • NCT00662779
    withdrawn; "High number of screen failures-couldn't find qualified subjects in timely manner"
  • NCT00706446
    terminated; "Funding was terminated"
  • NCT00819637
    terminated; "Unable to enroll r/t study design \& staffing issues. The trial terminated."
  • NCT01043601
    withdrawn; "Similar data obtained in another study \[see NCT01085045\], therefore study not implemented."
  • NCT01108627
    withdrawn; "Drug supply sponsor sent outdated drug"
9 further recorded trials
  • NCT01432080
    terminated; "Not meeting recruitment targets"
  • NCT01845025
    terminated; "Due to the action to withdraw the Foradil Aerolizer NDA in US; study was discontinued. This was a commercial reason and not due to any change in benefit-risk."
  • NCT01912872
    terminated; "Termination was due to identified errors in data management handling after an internal audit by the sponsor performed by third party."
  • NCT02275481
    terminated; "lack of enrollment"
  • NCT03181880
    withdrawn; "Study stopped early as AZ have re-prioritised to focus on research to help bring existing and innovative medicines to more patients with asthma and COPD."
  • NCT03219866
    terminated; "Lower enrollment than Sponsor expected - Sponsor stopped study"
  • NCT03662711
    terminated; "Contract terminated between AIFA and the Sponsor (University of Ferrara)"
  • NCT04611633
    terminated; "Due to COVID pandemic not feasible to include patients for this study"
  • NCT06282861
    terminated; "Delays in the opening and activation of participating sites, and a low recruitment rate, with only 48 participants enrolled over the course of one year"

recorded 2026-09-01 · last checked 2026-09-04

Human studies of Arformoterol used mometasone furoate/formoterol fumarate combination MDI 200/10 mcg BID — over how long?

Human studies of Arformoterol used "mometasone furoate/formoterol fumarate combination MDI 200/10 mcg BID". ClinicalTrials.gov · 2026-09-01

20 recorded entries; human; also "formoterol fumarate 10 mcg", "Mometasone Furoate/Formoterol Fumarate Combination MDI 100/10 mcg BID", "Formoterol Fumarate 10 mcg"

Show the evidence

human

  • NCT00383240
    mometasone furoate/formoterol fumarate combination MDI 200/10 mcg BID
  • NCT00383240
    formoterol fumarate 10 mcg
  • NCT00383552
    Mometasone Furoate/Formoterol Fumarate Combination MDI 100/10 mcg BID
  • NCT00383552
    Formoterol Fumarate 10 mcg
  • NCT00463567
    Formoterol (12 µg b.i.d.)
  • NCT00880490
    Formoterol Fumarate 12 mcg (Foradil Aerolizer)
14 more recorded rows
  • human NCT00961155
    formoterol 12 mcg twice daily
  • human NCT01013753
    Formoterol 12 mcg
  • human NCT01043601
    Formoterol Fumarate 12 µg (Foradil Aerolizer)
  • human NCT01049360
    Aclidinium 400 μg / Formoterol 12 μg
  • human NCT01049360
    Formoterol 12 μg
  • human NCT01078623
    Aclidinium 200 μg / formoterol 12 μg
  • human NCT01085045
    Formoterol Fumarate 12 μg (Foradil® Aerolizer®)
  • human NCT01349868
    Formoterol Fumarate 24 μg (Foradil® Aerolizer®)
  • human NCT01551888
    Aclidinium/formoterol 400/12μg
  • human NCT01787097
    Formoterol 24ug
  • human NCT02796651
    Formoterol fumarate (6 μg)
  • human NCT02796651
    Formoterol fumarate (12 μg)
  • human NCT02796651
    Formoterol fumarate (40 μg)
  • human NCT02796677
    Aclidinium bromide 400 μg/Formoterol Fumarate 12 μg (AB/FF 400/12 μg)

recorded 2026-09-01 · last checked 2026-09-04

Arformoterol's half-life is 14 days — which schedules were studied?

14 days, the half-life Arformoterol's label states: "In COPD patients given 15 mcg inhaled arformoterol twice a day for 14 days, the mean terminal half-life of arformoterol was 26 hours." DailyMed label · bb1a6643-f280-4f02-a824-0428a2b82d3c · 2026-08-20

Show the evidence
  • half life pharmacokinetics
    14 days; In COPD patients given 15 mcg inhaled arformoterol twice a day for 14 days, the mean terminal half-life of arformoterol was 26 hours.
  • metabolism pharmacokinetics
    Metabolism In vitro profiling studies in hepatocytes and liver microsomes have shown that arformoterol is primarily metabolized by direct conjugation (glucuronidation) and secondarily by O-demethylation.

recorded 2026-08-20 · last checked 2026-09-04

Which 55 trials of Arformoterol posted no result?

Posted no result
55 of 55 completed trials
Registrations
NCT00658255, NCT00685841, NCT00651651, NCT00651547, NCT00652002 and NCT00064402, and 49 more
Completion dates
oldest 2003-05; newest 2024-07-04
Show the evidence

Trial

  • NCT00658255
    2003-05
  • NCT00685841
    2003-06
  • NCT00651651
    2003-09
  • NCT00651547
    2003-10
  • NCT00652002
    2004-01
  • NCT00064402
    2004-03
14 further recorded trials
  • NCT00691405
    2004-05
  • NCT00064415
    2004-12
  • NCT00476268
    2005-01
  • NCT00742248
    2005-05
  • NCT00130351
    2005-08
  • NCT00215423
    2005-09
  • NCT00215384
    2005-10
  • NCT00215410
    2005-10
  • NCT00685529
    2005-10
  • NCT00134979
    2005-11
  • NCT00215371
    2005-11
  • NCT00215358
    2005-12
  • NCT00215397
    2005-12
  • NCT00280358
    2005-12

At the median, Arformoterol's trials enrolled 120 people — anything larger?

Median enrolment
120
Largest enrolment
10288
Registered trials counted
151

What do 9 spontaneous reports say about Arformoterol — and not say?

These are reports people sent to a regulator. They do not show the medicine caused the reaction. Nobody counted how many people took the medicine and reported nothing. The same event can be reported more than once, and many reports are incomplete. News coverage, lawsuits and new warnings change how often people report. A count is not a rate and not a risk.

Arformoterol appears in spontaneous reports to regulators. Across the 3 most-reported reaction terms, 9 reaction mentions were counted: chronic obstructive pulmonary disease 4; atelectasis 3; intestinal perforation 2. FAERS via Open Targets · CHEMBL1363 · 2026-06-24

Show the evidence
  • chronic obstructive pulmonary disease
    4
  • atelectasis
    3
  • intestinal perforation
    2

recorded 2026-06-24 · last checked 2026-09-04

Which 3 reactions does Arformoterol's label not list?

atelectasis, chronic obstructive pulmonary disease and intestinal perforation reported for Arformoterol, absent from its label. FAERS via Open Targets · CHEMBL1363 · 2026-06-24

2 label terms; 3 reported and unlisted; bb1a6643-f280-4f02-a824-0428a2b82d3c

Show the evidence
  • atelectasis
    count not stated
  • chronic obstructive pulmonary disease
    count not stated
  • intestinal perforation
    count not stated

recorded 2026-06-24 · last checked 2026-09-04

Arformoterol and CYP2D6, CYP1A2 and CYP2A6: shared by which compounds?

CYP2D6, CYP1A2 and CYP2A6 appear in Arformoterol's recorded interaction sentences, 8 in all. DailyMed label · bb1a6643-f280-4f02-a824-0428a2b82d3c · 2026-08-20

CYP1A2, CYP2A6, CYP2C19, CYP2C9, CYP2D6, CYP2D6; 9 shared nodes; pharmacokinetics, clinical_pharmacology

Show the evidence

Interaction statement

  • pharmacokinetics
    Two cytochrome P450 isozymes (CYP2D6 and secondarily CYP2C19) catalyze the O-demethylation of arformoterol.
  • pharmacokinetics
    Drug-Drug Interaction When paroxetine, a potent inhibitor of CYP2D6, was coadministered with arformoterol tartrate inhalation solution at steady-state, exposure to either drug was not altered.
  • pharmacokinetics
    Dosage adjustments of arformoterol tartrate inhalation solution are not necessary when the drug is given concomitantly with potent CYP2D6 inhibitors.
  • pharmacokinetics
    Arformoterol did not inhibit CYP1A2, CYP2A6, CYP2C9/10, CYP2C19, CYP2D6, CYP2E1, CYP3A4/5, or CYP4A9/11 enzymes at >1,000-fold higher concentrations than the expected peak plasma concentrations following a therapeutic dose.
  • clinical_pharmacology
    Two cytochrome P450 isozymes (CYP2D6 and secondarily CYP2C19) catalyze the O-demethylation of arformoterol.
  • clinical_pharmacology
    Drug-Drug Interaction When paroxetine, a potent inhibitor of CYP2D6, was coadministered with arformoterol tartrate inhalation solution at steady-state, exposure to either drug was not altered.
2 more recorded rows
  • Interaction statement clinical_pharmacology
    Dosage adjustments of arformoterol tartrate inhalation solution are not necessary when the drug is given concomitantly with potent CYP2D6 inhibitors.
  • Interaction statement clinical_pharmacology
    Arformoterol did not inhibit CYP1A2, CYP2A6, CYP2C9/10, CYP2C19, CYP2D6, CYP2E1, CYP3A4/5, or CYP4A9/11 enzymes at >1,000-fold higher concentrations than the expected peak plasma concentrations following a therapeutic dose.
  • CYP1A2
    FINGOLIMOD LAURYL SULFATE, FOSAPREPITANT DIMEGLUMINE, TAFAMIDIS MEGLUMINE, Arimoclomol, Rasagiline, Sofpironium, Golodirsen, Tinidazole
  • CYP2A6
    FINGOLIMOD LAURYL SULFATE, Rasagiline, Naldemedine, Methylnaltrexone, Tivozanib, Metaxalone, Selegiline, Trametinib
  • CYP2C19
    FINGOLIMOD LAURYL SULFATE, FOSAPREPITANT DIMEGLUMINE, TAFAMIDIS MEGLUMINE, Arimoclomol, Rasagiline, Golodirsen, Naldemedine, Etravirine
  • CYP2C9
    FINGOLIMOD LAURYL SULFATE, FOSAPREPITANT DIMEGLUMINE, TAFAMIDIS MEGLUMINE, Arimoclomol, Rasagiline, Golodirsen, Tinidazole, Naldemedine

CYP2D6

  • FINGOLIMOD LAURYL SULFATE, Darunavir Propylene Glycolate, FOSAPREPITANT DIMEGLUMINE, TAFAMIDIS MEGLUMINE, Arimoclomol, Rasagiline, Sofpironium, Fluoxetine
  • FINGOLIMOD LAURYL SULFATE, Darunavir Propylene Glycolate, FOSAPREPITANT DIMEGLUMINE, TAFAMIDIS MEGLUMINE, Arimoclomol, Rasagiline, Sofpironium, Fluoxetine
  • CYP2E1
    FINGOLIMOD LAURYL SULFATE, FOSAPREPITANT DIMEGLUMINE, Rasagiline, Tinidazole, Naldemedine, Methylnaltrexone, Alosetron, Metaxalone
  • CYP3A4
    FINGOLIMOD LAURYL SULFATE, ERYTHROMYCIN LACTOBIONATE, FOSAPREPITANT DIMEGLUMINE, TAFAMIDIS MEGLUMINE, Arimoclomol, Beclometasone, Rasagiline, Sofpironium
  • CYP4A9
    FINGOLIMOD LAURYL SULFATE, Fingolimod, Oxcarbazepine

recorded 2026-08-20 · last checked 2026-09-04

Where it is registered
Identifiers, relations and other names

The exact record

ChEMBL id
CHEMBL1363
PubChem CID
3083544
CAS number
67346-49-0
RxCUI
304962
InChIKey
BPZSYCZIITTYBL-YJYMSZOUSA-N
Also called
(-)-formoterol, Formoterol r,r-form, ARFORMOTEROL TARTRATE, (-)-N-(2-HYDROXY-5-((1R)-1-HYDROXY-2-(((1R)-2-(4-METHOXYPHENYL)-1-METHYLETHYL)AMINO)ETHYL)PHENYL)FORMAMIDE HYDROGEN (2R,3R)-2,3-DIHYDROXYBUTANEDIOATE (SALT), ARFORMOTEROL TARTRATE [MART.], ARFORMOTEROL TARTRATE [ORANGE BOOK], ARFORMOTEROL TARTRATE [USAN], ARFORMOTEROL TARTRATE [VANDF], Arformoterol tartrate [WHO-DD], FORMAMIDE, N-(2-HYDROXY-5-((1R)-1-HYDROXY-2-(((1R)-2-(4-METHOXYPHENYL)-1-METHYLETHYL)AMINO)ETHYL)PHENYL)-, (2R,3R)-2,3-DIHYDROXYBUTANEDIOATE (1:1) (SALT), FORMOTEROL R,R-FORM L-TARTRATE [MI]
Salt form
arformoterol tartrate inhalation solution, Formoterol r,r-form l-tartrate, Arformoterol Tartrate Inhalation, Arformoterol Tartrate Inhalation / Arformoterol Tartrate Inhalation Solution / Brovana, Formoterol Fumarate, Formoterol Fumarate Dihydrate, Formoterol Fumarate Inhalation Solution
Trade name
Brovana, Foradil, Perforomist, Foradil Certihaler, Foradil / Foradil Certihaler / Perforomist, Trimbow, Trydonis, Trixeo Aerosphere, Duaklir Genuair, Riarify (previously CHF 5993 Chiesi Farmaceutici S.p.A.)
Sources (6)

Sources

ChEMBL 37 — CC BY-SA 3.0 Unported · ClinicalTrials.gov — US Government work · Open Targets 26.06 — CC0 · mixed register set; per-register licences in docs/specs/corpus-20k-sources.md · openFDA / DailyMed — US Government work

How these records are assembled · Which registers were checked

Index-quality checks
  • identity passed: no open identity hold
  • required summary fields resolved: 4 required field(s) not terminal: Why people use it, Best-supported result, Biggest unanswered question, Human evidence
  • public claims reviewed: 0 reviewed claim(s); drafts are never rendered
  • source coverage passed: 6 source rows
  • no critical contamination: no quarantine open
  • canonical metadata passed: slug and display name present
  • no raw internal fields: enforced by the copy-contract test over the rendered page

This is a record of evidence. It is not medical advice, and it does not say this substance suits you. Nothing here says any substance on RNAWiki is appropriate for a child.